United Therapeutics reports Q3 2026 revenue up 4% to $832.5M, net income down 24%
United Therapeutics announced third‑quarter 2026 results showing total revenue of $832.5 million, a 4 % year‑over‑year increase. Net income fell 24 % to $258.6 million, driving diluted EPS down to $5.71. Revenue growth was led by a 13 % rise in Tyvaso DPI sales, while Nebulized Tyvaso declined 12 % amid competition. R&D spending surged 119 % to $279.2 million, largely reflecting the Thymmune Therapeutics acquisition and related in‑process R&D costs.
Why it matters
The company’s top‑line growth is offset by a sharp earnings decline, indicating higher expense pressure on profitability. The expanded $2 billion share‑repurchase program and strong cash position may support the stock price, but investors must weigh the impact of rising R&D outlays and competitive product pressures.
Key facts
- 1Total revenues for Q3 2026 were $832.5 million, up 4 % from $799.5 million in Q3 2025. sec.gov
- 2Net income for the quarter was $258.6 million, down 24 % from $338.7 million a year earlier. sec.gov
- 3Diluted earnings per share declined to $5.71 from $7.16, a 20 % decrease. sec.gov
- 4Tyvaso DPI sales increased 13 % to $378.5 million. sec.gov
- 5Nebulized Tyvaso revenue fell 12 % to $125.3 million. sec.gov
- 6Research and development expense rose 119 % to $279.2 million, driven by $125.2 million of other R&D costs related to the Thymmune acquisition. minichart.com.sg
Summary written by AlphAI AI Desk from 5 of 5 sources. Not investment advice. Figures are as stated by the linked sources.